Clinical Trial Update: Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria [Phase 2]

View source ↗

Summary

Phase 2 trial of MT-7117 in Erythropoietic Protoporphyria has completed and results have been posted. The study, sponsored by Tanabe Pharma America, Inc, evalua…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythropoietic Protoporphyria

Drugs mentioned

• MT-7117

Snippet

Sponsor: Tanabe Pharma America, Inc. | Conditions: Erythropoietic Protoporphyria (EPP) | Phase 2 | Status: COMPLETED | Results posted: 2023-01-20